Dr. James Kuo
Dr. James Kuo, MD, MBA is currently the Chief Executive Officer of the Finnish biotechnology company FIT Biotech Ltd. (NASDAQ: FITBIO). James Kuo is an experienced biotech industry executive and investor, who brings a wealth of business and management experience to the company. During his impressive career, he has held executive positions in private as well as listed biotech companies in the US. His most recent assignments have been as a CEO with Biomicro Systems, Inc. and Synthetic Biologics, Inc. (NYSE:SYN). Prior to that, he was CEO of Discovery Laboratories, Inc. (NASDAQ:DSCO) after having worked as Associate Director in corporate licensing and development at Pfizer Inc. (NYSE:PFE). James Kuo is presently Chairman of the Board at Athena Bioventures in La Jolla, CA.
A physician by training, James Kuo obtained his MBA at the Wharton School of the University of Pennsylvania. In addition he holds a BA in Molecular Biology.
Chief Executive Officer, President and Director
Thomas D’Orazio has served as Chief Executive Officer and President of ImmunoPrecise since August 28, 2016. Mr. D’Orazio is an experienced business executive with over 20 years in the life sciences and pharmaceutical industries where he has a successful track record building teams to develop and implement strategic growth plans. Mr. D’Orazio has worked for notable industry companies such as such as Pfizer, Merck and QLT. Mr. D’Orazio is also an entrepreneur who has founded or co-founded multiple life-sciences related companies. Mr. D’Orazio has a B.Sc. in Chemistry from Loyola University of Chicago and an MBA from Vanderbilt University.
Chief Technical Officer and Director
Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years.
Guy Champagne is an accomplished businessman and entrepreneur. Director of Seahawk Ventures (CNSX:SHX) since August 2015. From January, 2014, actively involved involving the management and operation of a group of 5 privately-owned companies including: President of Aequitor Inc., Vice-President of Real Estate Webmasters Inc., executive team member of ImmunoPrecise Antibodies Ltd., Hardy Buoys Smoked Fish Inc., and Atlas Engineered Wood Products Inc. Served as Managing Partner and Senior Partner of BDC Consulting between 2006 and 2013, retiring in December 2013. From 1974 to 2005, served as founder, executive, investor and consultant with numerous privately-held technology companies until their sale and disposition in 2005 to pursue retirement. Maintained designation as a Certified Management Consultant (Canadian Association of Certified Management Consultants) until 2016. During the late 1970’s and 1980’s and coincident with early success in business, pursued education including the Canadian Securities Course, the Canadian Institute of Chartered Business Valuators training program for the Chartered Business Valuator designation, and Honours Mathematics at McGill University.
Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (CSE: LTE).